IL24 and breast cancer: Notably, combined IL-24 and WP1066 treatment caused significantly more growth suppression in both MDA-MB-231 and HCC-1954 cells than each single treatment did, highlighting the therapeutic potential of co-targeting IL-24 and STAT3 in inhibiting BC cell growth.